HC Wainwright Analysts Decrease Earnings Estimates for RAPT

Rapt Therapeutics (NASDAQ:RAPT - Free Report) - HC Wainwright lowered their Q2 2025 earnings per share estimates for Rapt Therapeutics in a research note issued on Thursday, July 10th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.66) per share for the quarter, down from their previous estimate of ($0.64). HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Rapt Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Rapt Therapeutics' Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.19) EPS, FY2028 earnings at ($1.03) EPS and FY2029 earnings at ($1.09) EPS.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($2.48) by $1.84.

Other analysts have also recently issued reports about the company. UBS Group reduced their price objective on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Wall Street Zen cut Rapt Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $19.80.

Rapt Therapeutics Stock Down 1.9%

RAPT opened at $8.46 on Monday. Rapt Therapeutics has a 52 week low of $5.67 and a 52 week high of $30.60. The business has a fifty day simple moving average of $7.87 and a 200-day simple moving average of $8.79. The firm has a market cap of $139.93 million, a P/E ratio of -0.44 and a beta of -0.09.

Hedge Funds Weigh In On Rapt Therapeutics

Several institutional investors have recently added to or reduced their stakes in RAPT. TCG Crossover Management LLC acquired a new position in Rapt Therapeutics during the 4th quarter worth approximately $19,751,000. Orbimed Advisors LLC acquired a new position in Rapt Therapeutics during the 4th quarter worth approximately $20,754,000. Foresite Capital Management VI LLC acquired a new position in Rapt Therapeutics during the 4th quarter worth approximately $19,750,000. RTW Investments LP acquired a new position in Rapt Therapeutics during the 4th quarter worth approximately $18,587,000. Finally, BVF Inc. IL acquired a new position in Rapt Therapeutics during the 4th quarter worth approximately $14,595,000. Institutional investors and hedge funds own 99.09% of the company's stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.